Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2018 · New England Journal of Medicine · 2,701 citations
https://doi.org/10.1056/nejmoa1810858
A
Ana Oaknin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
710
Papers
35.6K
Citations
71
h-index
209
i10-index
Ana Oaknin is an academic researcher from Hebron University. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & PARP inhibition in cancer therapy & Endometrial and Cervical Cancer Treatments. The author has an h-index of 71, co-authored 604 publications.
ORCID: 0000-0002-3592-7194Papers by this author
worksVeliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
2019 · New England Journal of Medicine · 886 citations
https://doi.org/10.1056/nejmoa1909707
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 · Journal of Clinical Oncology · 809 citations
https://doi.org/10.1200/jco.23.02005
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
2019 · Journal of Clinical Oncology · 423 citations
https://doi.org/10.1200/jco.19.00739
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 · Journal of Clinical Oncology · 334 citations
https://doi.org/10.1200/jco.22.01900
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
2021 · Annals of Oncology · 265 citations
https://doi.org/10.1016/j.annonc.2021.02.017
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat